<p>The German biotechnology company BioNTech plans to reduce the production scale of its cell therapy at its first factory in the United States due to its CAR-T candidate drug not meeting expectations in early cancer trials. By the end of this summer, BioNTech's cell therapy factory in Gaithersburg, Maryland, will lay off 63 employees, mainly affecting the cell therapy technical operations team at the site</p>

BNTX

<p>German biotechnology company BioNTech plans to reduce the production scale of its cell therapy at its first factory in the United States, as its CAR-T candidate drug did not meet expectations in early cancer trials. By the end of this summer, BioNTech's cell therapy factory in Gaithersburg, Maryland, will lay off 63 employees, primarily affecting the cell therapy technical operations team at the site</p>

BioNTech shrinks CAR-T front, lays off 63 people